COVID-19NCT04424797
Prone Positioning on Admission for Hospitalized COVID-19 Pneumonia Protocol
A study testing Prone Positioning and Supine Positioning in people with COVID-19, run by Poudre Valley Health System at 3 sites in United States.
Trial summary
A pilot study to investigate the effects of the prone positioning (PP) on hospital patients diagnosed with COVID-19 pneumonia. Investigators that early self-proning may prevent intubation and improve mortality in patients with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- COVID-19
- What is being tested?
- Prone Positioning and Supine Positioning
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 3 sitesUnited States
- Study dates
- 13 Jul 2020to 31 Jul 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients admitted to the hospital floor with primary diagnosis of confirmed COVID-19 pneumonia and respiratory failure requiring greater than or equal to 2 Liters(L) Nasal Cannula (NC) to maintain SpO2>90%
- Ability to independently change positions in bed
- Able to tolerate prone positioning
- Age greater than 18
Who cannot join
- ICU admission on arrival
- Respiratory distress requiring immediate intubation
- Respiratory Rate(RR)>35/min, accessory respiratory muscle use (ex. speaking in short sentences), signs of respiratory muscle fatigue, altered mental status, or inability to protect airway
- Chest or facial trauma, pneumothorax or other contraindication to prone positioning (i.e., spinal instability, recent abdominal surgery, pregnancy, etc)
- Hemodynamically unstable
- Heart Rate (HR)>120 bpm, Systolic Blood Pressure (SBP)<90 mmHg, Mean Arterial Pressure (MAP)<65 mmHg or requirement for vasopressor
Show all 9Show fewer
- Nausea and vomiting
- Pregnancy
- Refusal or inability to tolerate initial prone positioning due to comfort
Trial locations and contacts
3 sites in 1 country.
United States3 sites, 3 recruiting
- Recruiting
UCHealth Poudre Valley Hospital
Fort Collins, Colorado, 80524
Research Manager
Lucie Uncapher, MD
- Recruiting
UCHealth Greeley Hospital
Greeley, Colorado, 80634
Research Manager
Lucie Uncapher, MD
- Recruiting
UCHealth Medical Center of the Rockies
Loveland, Colorado, 80538
Research Manager
Lucie Uncapher, MD
About this study
A pilot study to investigate the effects of the prone positioning (PP) on hospital patients diagnosed with COVID-19 pneumonia.
Investigators that early self-proning may prevent intubation and improve mortality in patients with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2).
Read more
Up to 100 participants with a primary diagnosis of confirmed COVID-19 pneumonia will be enrolled to the study.
All participants will be screened and those that meet inclusion and exclusion criteria will be enrolled to one of two groups: one with prone positioning (on the belly) and the other with standard supine positioning (on the back). The patient and nursing staff will monitor times spent in various positions.
Outcome measures include incidence of intubation, max oxygen requirements, length of hospital stay, ventilator-free days, worsening of oxygenation saturation, and mortality.
Read the detailed description
In hypoxic respiratory failure, placing patients in the prone position improves ventilation to perfusion matching, alveolar recruitment, and alveolar to arterial oxygen gradients. Specifically, in Acute Respiratory Distress Syndrome ARDS, proning intubated patients improves overall mortality. With the emergence of SARS-COV-2, hospitals around the world have seen a marked increase in patients with acute hypoxic respiratory failure and ARDS. This surge in cases has prompted a search for more effective strategies to reduce intubation and improve patient morbidity and mortality. One such strategy is that of voluntary proning, in which awake patients are instructed to prone themselves (Early PP With High Flow Nasal Cannula (HFNC) Versus HFNC in COVID-19 Induced Moderate to Severe ARDS) (COVID-19 smArtphone-based Trial of Non-ICU Admission Prone Positioning (CATNAP)).
This trial proposes a voluntary proning strategy in patients admitted to the hospital, not yet requiring mechanical ventilation. Given the clear evidence that proning improves outcomes in ARDS, investigators hypothesize that early, voluntary self-proning may prevent intubation and improve mortality in patients with SARS-COV-2.
Methods
This is a pilot study of up to 100 participants at UCHealth facilities.
Patients will be assessed if they can self prone safely and be assessed against inclusion and exclusion criteria within 12 hours of admission and randomized to either prone or supine positioning. Baseline labs will be measured and all participants will be monitored continuously via pulse oximetry.
The Standard Supine Control Group will utilize standard oxygen (O2) device in supine position at approximately 30-60 degrees to target peripheral capillary oxygen saturation (SpO2) >90% and the participant or nurse will document time in non-supine position.
The Prone Experimental Group will position patient in approximately 15-degree reverse trendelenburg and prone using pillows for comfort. The participant will be asked to rotate to prone positioning every 2 hours while awake and encourage to sleep prone overnight as possible with a goal of 10-12 hours daily. Patient to log all time prone.
Treatment Failure may occur and termination of Intermittent Prone Positioning will occur. This is defined as respiratory distress or a decrease in O2 saturations <90% for more than 2 minutes as determined by bedside nursing or per virtual pulse oximetry monitoring notifications during the study on two consecutive occasions. The participant will be returned to supine positioning and follow standard supine oxygenation. The participant can be re-challenged in the prone position after the participant stabilizes for 2 hours. The participant can also choose to stop proning and would be considered a treatment failures.
Statistical Analysis and Sample Size In New York City the intubation rate has been reported at 1/3 of COVID-19 positive patients admitted to the hospital. The table below shows the sample size needed for a binomial outcome of intubation when 50% of the sample is randomized to Prone Positioning (PP):
Alpha 0.05 0.05 0.05 0.05 Beta 0.80 0.80 0.80 0.80 Probability of intubation with PP 0.05 0.10 0.15 0.20 Probability of intubation 0.33 0.33 0.33 0.33 Proportion receiving PP 0.50 0.50 0.50 0.50 Sample size 33 39 56 97
Expecting a 13% decrease in intubations with the prone position, investigators will use a sample size of N = 100 (50 per group) in order to have 80% power with a two-sided alpha = 0.05 for logistic regression. ANCOVA will be used to evaluate continuous, secondary variables in order to adjust for covariates. The study is powered for the primary outcome of intubation or no intubation. No adjustments will be made for the secondary endpoints.
The investigators and statistician will validate the data and the study will be subject to institutional quality assurance reviews.
- Conditions
- COVID-19
- Being tested
- Prone Positioning, Supine Positioning
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Prone PositioningOther
Intervention is patient in prone positioning
Supine PositioningOther
Intervention is patient in supine positioning
| Study group | Role | What they receive |
|---|---|---|
| Prone Positioning | Experimental | Prone positioning Receives: Other: Prone Positioning |
| Supine Positioning | Other | Supine Positioning Receives: Other: Supine Positioning |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of intubation
Incidence of intubation
Measured: Through study completion, an average of 6 days
Secondary outcomes (5)
Maximum oxygen requirement
Measure of maximum oxygen requirements
Measured: Through study completion, an average of 6 days
Length of Stay
Measured in days of hospitalization
Measured: Through study completion, an average of 6 days
Ventilator-free days
Measured in days not on a ventilator
Measured: Through study completion, an average of 6 days
Treatment failure of prone positioning due to worsening SpO2 status while prone
Whether or not the participant met treatment failure descriptions
Measured: Through study completion, an average of 6 days
Mortality
Whether or not the participant died while hospitalized
Measured: Through study completion, an average of 6 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jun 2020
- Study start13 Jul 2020
- Primary completion31 Jul 2022 (estimated)
- Study completion31 Jul 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID-19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Prone vs. Supine positioning
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Poudre Valley Health System
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Lucie Uncapher, Poudre Valley Health System
- Investigators
- Lucie Uncapher, Principal investigator, University of Colorado Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04424797
- Sponsor's protocol ID
- 20-6034
- Status last verified
- Apr 2022
- First submitted
- 5 Jun 2020
- Last updated
- 25 Apr 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Apr 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prone Positioning on Admission for Hospitalized COVID-19 Pneumonia Protocol
- ClinicalTrials.gov ID
- NCT04424797
- Acronym / sponsor ID
- 20-6034
- Conditions
- COVID-19
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Poudre Valley Health SystemUniversity, hospital or other
- Study start
- 13 Jul 2020 (actual)
- Primary completion
- 31 Jul 2022 (estimated)
- Study completion
- 31 Jul 2022 (estimated)
- First posted
- 11 Jun 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A pilot study to investigate the effects of the prone positioning (PP) on hospital patients diagnosed with COVID-19 pneumonia.
Investigators that early self-proning may prevent intubation and improve mortality in patients with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2).
Up to 100 participants with a primary diagnosis of confirmed COVID-19 pneumonia will be enrolled to the study.
All participants will be screened and those that meet inclusion and exclusion criteria will be enrolled to one of two groups: one with prone positioning (on the belly) and the other with standard supine positioning (on the back). The patient and nursing staff will monitor times spent in various positions.
Outcome measures include incidence of intubation, max oxygen requirements, length of hospital stay, ventilator-free days, worsening of oxygenation saturation, and mortality.
Detailed description
In hypoxic respiratory failure, placing patients in the prone position improves ventilation to perfusion matching, alveolar recruitment, and alveolar to arterial oxygen gradients. Specifically, in Acute Respiratory Distress Syndrome ARDS, proning intubated patients improves overall mortality. With the emergence of SARS-COV-2, hospitals around the world have seen a marked increase in patients with acute hypoxic respiratory failure and ARDS. This surge in cases has prompted a search for more effective strategies to reduce intubation and improve patient morbidity and mortality. One such strategy is that of voluntary proning, in which awake patients are instructed to prone themselves (Early PP With High Flow Nasal Cannula (HFNC) Versus HFNC in COVID-19 Induced Moderate to Severe ARDS) (COVID-19 smArtphone-based Trial of Non-ICU Admission Prone Positioning (CATNAP)).
This trial proposes a voluntary proning strategy in patients admitted to the hospital, not yet requiring mechanical ventilation. Given the clear evidence that proning improves outcomes in ARDS, investigators hypothesize that early, voluntary self-proning may prevent intubation and improve mortality in patients with SARS-COV-2.
Methods
This is a pilot study of up to 100 participants at UCHealth facilities.
Patients will be assessed if they can self prone safely and be assessed against inclusion and exclusion criteria within 12 hours of admission and randomized to either prone or supine positioning. Baseline labs will be measured and all participants will be monitored continuously via pulse oximetry.
The Standard Supine Control Group will utilize standard oxygen (O2) device in supine position at approximately 30-60 degrees to target peripheral capillary oxygen saturation (SpO2) >90% and the participant or nurse will document time in non-supine position.
The Prone Experimental Group will position patient in approximately 15-degree reverse trendelenburg and prone using pillows for comfort. The participant will be asked to rotate to prone positioning every 2 hours while awake and encourage to sleep prone overnight as possible with a goal of 10-12 hours daily. Patient to log all time prone.
Treatment Failure may occur and termination of Intermittent Prone Positioning will occur. This is defined as respiratory distress or a decrease in O2 saturations <90% for more than 2 minutes as determined by bedside nursing or per virtual pulse oximetry monitoring notifications during the study on two consecutive occasions. The participant will be returned to supine positioning and follow standard supine oxygenation. The participant can be re-challenged in the prone position after the participant stabilizes for 2 hours. The participant can also choose to stop proning and would be considered a treatment failures.
Statistical Analysis and Sample Size In New York City the intubation rate has been reported at 1/3 of COVID-19 positive patients admitted to the hospital. The table below shows the sample size needed for a binomial outcome of intubation when 50% of the sample is randomized to Prone Positioning (PP):
Alpha 0.05 0.05 0.05 0.05 Beta 0.80 0.80 0.80 0.80 Probability of intubation with PP 0.05 0.10 0.15 0.20 Probability of intubation 0.33 0.33 0.33 0.33 Proportion receiving PP 0.50 0.50 0.50 0.50 Sample size 33 39 56 97
Expecting a 13% decrease in intubations with the prone position, investigators will use a sample size of N = 100 (50 per group) in order to have 80% power with a two-sided alpha = 0.05 for logistic regression. ANCOVA will be used to evaluate continuous, secondary variables in order to adjust for covariates. The study is powered for the primary outcome of intubation or no intubation. No adjustments will be made for the secondary endpoints.
The investigators and statistician will validate the data and the study will be subject to institutional quality assurance reviews.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Prone vs. Supine positioning
| Arm | Type | Receives |
|---|---|---|
| Prone Positioning | Experimental | Other: Prone PositioningProne positioning |
| Supine Positioning | Other | Other: Supine PositioningSupine Positioning |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Patients admitted to the hospital floor with primary diagnosis of confirmed COVID-19 pneumonia and respiratory failure requiring greater than or equal to 2 Liters(L) Nasal Cannula (NC) to maintain SpO2>90%
- Ability to independently change positions in bed
- Able to tolerate prone positioning
- Age greater than 18
Key exclusion criteria (9 listed)
- ICU admission on arrival
- Respiratory distress requiring immediate intubation
- Chest or facial trauma, pneumothorax or other contraindication to prone positioning (i.e., spinal instability, recent abdominal surgery, pregnancy, etc)
- Hemodynamically unstable
- Nausea and vomiting
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Prone PositioningIntervention is patient in prone positioning | Other | Prone Positioning |
| Supine PositioningIntervention is patient in supine positioning | Other | Supine Positioning |
Primary outcome
Incidence of intubation
Time frame: Through study completion, an average of 6 days
Incidence of intubation
5 secondary outcomes
Maximum oxygen requirement
Time frame: Through study completion, an average of 6 days
Length of Stay
Time frame: Through study completion, an average of 6 days
Ventilator-free days
Time frame: Through study completion, an average of 6 days
Treatment failure of prone positioning due to worsening SpO2 status while prone
Time frame: Through study completion, an average of 6 days
Mortality
Time frame: Through study completion, an average of 6 days
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Apr 2022.
- Individual participant dataSharing planned: No
Related trials for COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lucie Uncapher principal investigator
University of Colorado Health
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Prone Positioning and Supine Positioning in people with COVID-19, run by Poudre Valley Health System at 3 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 25 Apr 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Sara Twombly, MACI CCRC (970-297-6188, sara.twombly@uchealth.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of intubation (time frame: Through study completion, an average of 6 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Apr 2022.